CoChat
Sign Up
Cited by 258Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and TreatmentsManagement of metastatic bone disease

UK guidelines for the management of bone sarcomas

Open access
On behalf of the British Sarcoma Group, Gerrand, Craig, Athanasou, Nick, Brennan, Bernadette, Grimer, Robert, Judson, Ian, Morland, Bruce, Peake, David +2 more·2016·Clinical Sarcoma Research
DOI 10.1186/s13569-016-0047-1PMC PMC4855334
Open this paper in CoChat — free account

Abstract

This document is an update of the British Sarcoma Group guidelines published in 2010. The aim is to provide a reference standard for the clinical care of patients in the UK with bone sarcomas. Recent recommendations by the European Society of Medical Oncology, The National Comprehensive Cancer Network and The National Institute for Health and Care Excellence have been incorporated, and the literature since 2010 reviewed. The standards represent a consensus amongst British Sarcoma Group members in 2015. It is acknowledged that these guidelines will need further updates as care evolves. The key recommendations are that bone pain or a palpable mass should always lead to further investigation and that patients with clinico-radiological findings suggestive of a primary bone tumour at any site in the skeleton should be referred to a specialist centre and managed by a fully accredited bone sarcoma multidisciplinary team. Treatment recommendations are provided for the major tumour types and for localised, metastatic and recurrent disease. Follow up schedules are suggested.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13569-016-0047-1

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • During the last 30 years, many new approaches to the treatment of bone sarcomas have failed to improve 5-year overall survival.

    “During the last 30 years, many new approaches to the treatment of bone sarcomas have been developed; however, these have failed to improve 5-year overall survival [8].”

    From Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice (2019) · cites this paper as [8]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 159

  1. [2]Grimer R Athanasou N Gerrand C Judson I Lewis I Morland B Peake D Seddon B Whelan J UK guidelines for the management of bone sarcomas Sarcoma. 2010 317462 14 PMC3022187 21253474
  2. [4]The ESMO/European Sarcoma Network Working Group Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol. 2014 25 Suppl 3 113 123 10.1093/annonc/mdu256 25210081 · DOI
  3. [6]National Institute for Health and Care Excellence (NICE) Suspected cancer: recognition and referral NICE guideline [NG12]; 2015. http://www.nice.org.uk/guidance/ng12. Accessed 21 Sep 2015. 26180880
  4. [8]Grimer RJ Briggs TR Earlier diagnosis of bone and soft tissue tumours J Bone Joint Surg Br. 2010 92 11 1489 1492 10.1302/0301-620X.92B11.24326 21037340 · DOI
  5. [9]Stiller CA Craft AW Corazziari I EUROCARE Working Group. Survival of children with bone sarcoma in Europe since Results from the EUROCARE study Eur J Cancer 1978 2001 37 760 766 11311651
  6. [10]Kager L Zoubek A Dominikus M Lang S Bodmer N Jundt G Klingebiel T Jürgens H Gadner H Bielack S COSS study group. Osteosarcoma in very young children: experience of the cooperative osteosarcoma study group Cancer 2010 116 22 5316 5324 10.1002/cncr.25287 20672353 · DOI
  7. [11]Malhas AM Grimer RJ Abudu A Carter SR Tillman RM Jeys L The final diagnosis in patients with a suspected primary malignancy of bone J Bone Joint Surg Br 2011 93 980 983 10.1302/0301-620X.93B7.25727 21705575 · DOI
  8. [12]Hauben EI Hogendoorn PCW Heymann D Epidemiology of primary bone tumors and economical aspects of bone metastases Bone cancer: progression and therapeutic approaches 2009 1 London Academic Press 3 8
  9. [13]Whelan JS Jinks RC McTiernan A Sydes MR Hook JM Trani L Uscinska B Bramwell V Lewis IJ Nooij MA Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised trials Ann Oncol 2012 23 1607 1616 10.1093/annonc/mdr491 22015453 PMC3360547 · DOI
  10. [14]Fletcher CD Bridge JA Hogendoorn P Mertens F WHO classification of tumours of soft tissue and bone 2013 4 Lyon France IARC Press
  11. [15]Eyre R Feltbower RG Mubwandarikwa E Eden TO McNally RJ Review: epidemiology of bone tumours in children and young adults Pediat Blood Cancer. 2009 53 941 952 10.1002/pbc.22194 19618453 · DOI
  12. [16]Kalra S Grimer RJ Spooner D Carter SR Tillman RM Abudu A Radiation induced sarcomas of bone. Factors that affect outcome J Bone Joint Surg Br 2007 89B 808 813 10.1302/0301-620X.89B6.18729 17613509 · DOI
  13. [18]Dorfman HD Czerniak B Bone Cancers Cancer 1995 75 203 210 10.1002/1097-0142(19950101)75:1+<203::AID-CNCR2820751308>3.0.CO;2-V 8000997 · DOI
  14. [19]Mascarenhas L, Siegel S, Spector L, Arndt C, Femino D, Malogolowkin M. Malignant bone tumours. SEER AYA Monograph, Chapter 8. 2002. p. 97–109.
  15. [20]Fuchs B Pritchard DJ Etiology of osteosarcoma Clinical Orthop Rel Res. 2002 397 40 52 10.1097/00003086-200204000-00007 11953594 · DOI
  16. [21]Hansen MF Seton M Merchant A Osteosarcoma in Paget’s disease of bone J Bone Min Res. 2006 21 Suppl 2 58 63 10.1359/jbmr.06s211 17229010 · DOI
  17. [22]Specht K Sung YS Zhang L Richter GHS Fletcher CD Antonescu CR Distinct transcriptional signature and immunoprofile of CIC-DUX4-fusion positive round cell tumors compared to EWSR1-rearranged Ewing sarcomas– further evidence toward distinct pathological entities Genes Chromosome Cancer. 2014 53 7 622 633 10.1002/gcc.22172 PMC4108073 24723486 · DOI
  18. [23]Bernstein M Kovar H Paulussen M Randall RL Schuck A Teot LA Jüergens H Ewing’s sarcoma family of tumors: current management Oncologist. 2006 11 503 519 10.1634/theoncologist.11-5-503 16720851 · DOI
  19. [24]Paulussen M Bielack S Jürgens H Casali PG ESMO Guidelines Working Group Ewing’s sarcoma of the bone: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol. 2009 20 4 140 142 19454436
  20. [26]Lai X Chen S Identification of novel biomarker candidates for immunohistochemical diagnosis to distinguish low-grade chondrosarcoma from echondroma Proteonomic. 2015 15 13 2358 2368 10.1002/pmic.201400528 25755173 · DOI
  21. [27]Verdegaal SH Bovee JV Pansuriya TC Grimer RJ Ozger H Jutte PC San Julian M Biau DJ van der Geest IC Leithner A Incidence, predictive factors and prognosis of chondrosarcoma in patients with Ollier Disease and Maffucci Syndrome: an International Multicenter Study of 161 patients Oncologist 2011 16 1771 1779 10.1634/theoncologist.2011-0200 22147000 PMC3248776 · DOI
  22. [28]Eefting D Schrage YM Geirnaerdt MJ Le Cessie S Taminiau AH Bovée JV Hogendoorn PC EuroBoNeT consortium. Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors Am J Surg Pathol 2009 33 50 57 10.1097/PAS.0b013e31817eec2b 18852676 · DOI
  23. [29]Gelderblom H Hogendoorn PCW Dijkstra SD van Rijswijk CS Krol AD Taminiau AH Bovée JV The clinical approach towards chondrosarcoma Oncologist. 2008 13 320 329 10.1634/theoncologist.2007-0237 18378543 · DOI
  24. [30]Riedel RF Larrier N Dodd L Kirsch D Martinez S Brigman BE The clinical management of chondrosarcoma Curr Treat Options Oncol 2009 10 94 106 10.1007/s11864-009-0088-2 19238552 · DOI
  25. [31]Grimer RJ Gosheger G Taminiau A Biau D Matejovsky Z Kollender Y San-Julian M Gherlinzoni F Ferrari C Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group Eur J Cancer 2007 43 2060 2065 10.1016/j.ejca.2007.06.016 17720491 · DOI
  26. [32]Romeo S Bovee JV Kroon HM Tirabosco R Natali C Zanatta L Sciot R Mertens F Athanasou N Alberghini M Malignant fibrous histiocytoma and fibrosarcoma of bone: a reassessment in the light of currently employed morphological, immunochemical and molecular approaches Virchows Arch 2012 461 561 570 10.1007/s00428-012-1306-z 23001328 · DOI
  27. [33]Doyle LA Sarcoma classification: an update based on the 2013 World Health Organization classification of tumors of soft tissue and bone Cancer 2014 120 1763 1774 10.1002/cncr.28657 24648013 · DOI
  28. [34]Jeon DG Song WS Kong CB Kim JR Lee SY MFH of bone and osteosarcoma show similar survival and chemosensitivity Clin Orthop Rel Res. 2011 469 584 590 10.1007/s11999-010-1428-z PMC3018190 20559764 · DOI
  29. [35]Stacchiotti S Sommer J on behalf of a chordoma global consensus group: a position paper from the medical and patient community Lancet Oncol. 2015 16 2 e71 e83 10.1016/S1470-2045(14)71190-8 25638683 · DOI
  30. [36]Giannoulis DK Gantsos A Giotis D Paschos NK Vagionas A Arnaoutoglou CM Pentheroudakis G Xenakis TA Multiple recurrences and late metastasis of adamantinoma in the tibia: a case report J Orthop Surg. 2014 22 3 420 422 25550030
  31. [37]Roque P Mankin HJ Rosenberg A Adamantinoma: an unusual bone tumour Chir Organi Mov 2008 92 3 149 154 10.1007/s12306-008-0060-5 19030952 · DOI
  32. [38]Viswanathan S Jambhekar NA Metastatic giant cell tumor of bone: are there associated factors and best treatment modalities? Clin Orthop Rel Res. 2010 468 3 827 833 10.1007/s11999-009-0966-8 PMC2816751 19597900 · DOI
  33. [39]Bergovec M Kubat O Smerdelj M Seiwerth S Bonevski A Orlic D Epidemiology of musculoskeletal tumors in a national referral orthopedic department A study of 3482 cases Cancer Epidemiol. 2015 39 3 298 302 10.1016/j.canep.2015.01.015 25703268 · DOI
  34. [40]Campanacci M Giunti A Olmi R Metaphyseal and diaphyseal localization of giant cell tumors Chir Organi Mov 1975 62 1 29 34 1095318
  35. [41]Pakos EE Grimer RJ Peake D Spooner D Carter SR Tillman RM Abudu S Jeys L The other bone sarcomas: prognostic factors and outcomes for spindle cell sarcomas of bone J Bone Joint Surg Br. 2011 93 9 1271 1278 10.1302/0301-620X.93B9.27166 21911541 · DOI
  36. [42]Whelan JS Pollock RC Cassoni M Windsor RE Price P Sikora K Primary bone tumours Treatment of cancer 2014 6 Boca Raton CRC Press
  37. [43]Grimer RJ Sneath RS Diagnosing malignant bone tumours J Bone Joint Surg Br 1990 72B 754 756 2211748
  38. [44]Pizzo PA, Poplack DG. Osteosarcoma: principles and practice of pediatric oncology, 5th edn. 2006;35:1074–115.
  39. [45]Bielack SS Machatschek JN Flege S Jürgens H Delaying surgery with chemotherapy for osteosarcoma of the extremities Exp Opin Pharmacother. 2004 5 1243 1256 10.1517/14656566.5.6.1243 15163270 · DOI
  40. [46]Federman N Bernthal N Eilber FC Tap WD The multidisciplinary management of osteosarcoma Curr Treat Opt Oncol 2009 10 82 93 10.1007/s11864-009-0087-3 19238553 · DOI
  41. [47]National Institute for Health and Care Excellence (NICE). Guidance on cancer services—improving outcomes for people with sarcoma: the manual [needs assessment, evidence review, list of recommendations]; 2006. (Developed by the National Collaborating Centre for Cancer).
  42. [49]Mankin HJ Lange TA Spanier SS The hazards of biopsy in patients with malignant primary bone and soft-tissue tumors J Bone Joint Surg Ser A. 1982 64 8 1121 1127 7130225
  43. [50]Andreou D Bielack DD Carrle D Kevric M Kotz R Winkelmann W Jundt G Werner M Fehlberg S Kager L The influence of tumor- and treatment-related factors on the development of local recurrence in osteosarcoma after adequate surgery. An analysis of 1335 patients treated on neoadjuvant Cooperative Osteosarcoma Group protocols Ann Oncol 2011 22 1228 1235 10.1093/annonc/mdq589 21030381 · DOI
  44. [54]Picci P Vanel D Briccoli A Talle K Haakenaasen U Malaguti C Monti C Ferrari C Bacci G Saeter G Computed tomography of pulmonary metastases from osteosarcoma: the less poor technique. A study of 51 patients with histological correlation Ann Oncol 2001 12 1601 1604 10.1023/A:1013103511633 11822761 · DOI
  45. [55]Wang S Shi H Yu Q Osteosarcoma of the jaws: demographic and CT imaging features Dentomaxillofacial Radiol. 2012 41 37 42 10.1259/dmfr/86834844 PMC3520269 22074870 · DOI
  46. [56]Benz MR Tchekmedyian N Eilber FC Federman N Czernin J Tap WD Utilization of positron emission tomography in the management of patients with sarcoma Curr Opin Oncol 2009 21 345 351 10.1097/CCO.0b013e32832c95e2 19412096 · DOI
  47. [57]Newman EN Jones RL Hawkins DS An evaluation of [F-18]-fluorodeoxy-d-glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing sarcoma Pediatr Blood Cancer 2013 60 7 1113 1117 10.1002/pbc.24406 23192939 · DOI
  48. [58]Quartuccio N Fox J Kuk D Wexler LH Baldari S Cistaro A Schöder H Pediatric bone sarcoma: diagnostic performance of (18)F-FDG PET/CT versus conventional imaging for initial staging and follow-up Am J Roentgenol 2015 204 1 153 160 10.2214/AJR.14.12932 25539251 · DOI
  49. [59]Bajpai J Gamnagatti S Kumar R Sreenivas V Sharma MC Khan SA Rastogi S Malhotra A Safaya R Bakhshi S Role of MRI in osteosarcoma for evaluation and prediction of chemotherapy response: correlation with histological necrosis Pediatr Radiol 2011 41 441 450 10.1007/s00247-010-1876-3 20978754 · DOI
  50. [60]Enneking WF Spanier SS Goodman MA A system for the surgical staging of musculoskeletal sarcoma Clin Orthop 1980 53 106 120 7449206
  51. [61]Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (Eds.) AJCC Cancer Staging Manual, 7th edn. New York, NY: Springer 2010.
  52. [62]Bramer JA van Linge JH Grimer RJ Scholten RJ Prognostic factors in localized extremity osteosarcoma: a systematic review Eur J Surg Oncol 2009 35 1030 1036 10.1016/j.ejso.2009.01.011 19232880 · DOI
  53. [63]Leavey PJ Collier AB Ewing sarcoma: prognostic criteria, outcomes and future treatment Exp Rev Anticancer Ther. 2008 8 617 624 10.1586/14737140.8.4.617 18402528 · DOI
  54. [64]Carrle D Bielack SS Current strategies of chemotherapy in osteosarcoma Int Orthop 2006 30 445 451 10.1007/s00264-006-0192-x 16896870 PMC3172747 · DOI
  55. [65]Altuntas AO Slavin J Smith PJ Schlict SM Powell GJ Ngan S Toner G Choong PF Accuracy of computed tomography guided core needle biopsy of musculoskeletal tumours ANZ J Surg. 2005 75 187 191 10.1111/j.1445-2197.2005.03332.x 15839962 · DOI
  56. [66]Pramesh CS Deshpande MS Pardiwala DN Agarwal MG Puri A Core needle biopsy for bone tumours Eur J Surg Oncol 2001 27 668 671 10.1053/ejso.2001.1198 11669596 · DOI
  57. [69]Machado I Noguera R Pellin A Lopez-Guerrero JA Piqueras M Navarro S Llombart-Bosch A Molecular diagnosis of Ewing sarcoma family of tumors: a comparative analysis of 560 cases with FISH and RT-PCR Diag Mol Pathol. 2009 18 189 199 10.1097/PDM.0b013e3181a06f66 19861898 · DOI
  58. [72]Burgert EO Nesbit ME Garnsey LA Gehan EA Herrmann J Vietti TJ Cangir A Tefft M Evans R Thomas P Multimodal therapy for the management of nonpelvic, localized Ewing’s sarcoma of bone: intergroup study IESS-II J Clin Oncol 1990 8 1514 1524 2099751
  59. [73]Anninga JK Gelderblom H Fiocco M Kroep JR Taminiau AH Hogendoorn PC Egeler RM Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer. 2011 16 2431 2445 10.1016/j.ejca.2011.05.030 21703851 · DOI · Paper page
  60. [74]Delaney T Liebsch NJ Pedlow FX Adams J Dean S Yeap BY McManus P Rosenberg AE Nielsen GP Harmon DC Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas Int J Radiat Oncol Biol Phys 2009 74 3 732 739 10.1016/j.ijrobp.2008.08.058 19095372 PMC2734911 · DOI
  61. [76]Blattmann C Oertel S Schulz-Ertner D Rieken S Haufe S Ewerbeck V Unterberg A Karapanagiotou-Schenkel I Combs SE Nikoghosyan A Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma BMC Cancer 2010 10 96 10.1186/1471-2407-10-96 20226028 PMC2846886 · DOI
  62. [77]Noël G Feuvret L Ferrand R Boisserie G Mazeron JJ Habrand JL Radiotherapeutic factors in the management of cervical-basal chordomas and chondrosarcomas Neurosurgery. 2004 55 1252 1260 15574207
  63. [78]Ares C Hug EB Lomax AJ Bolsi A Timmermann B Rutz HP Schuller JC Pedroni E Goitein G Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term result Int J Radiat Oncol Biol Phys 2009 75 4 1111 1118 10.1016/j.ijrobp.2008.12.055 19386442 · DOI
  64. [79]Yasuda M Bresson D Chibbaro S Cornelius JF Polivka M Feuvret L Takayasu M George B Chordomas of the skull base and cervical spine: clinical outcomes associated with a multimodal surgical resection combined with proton-beam radiation in 40 patients Neurosurg Rev. 2012 35 2 171 182 10.1007/s10143-011-0334-5 21863225 · DOI
  65. [80]Ciernik IF Niemierko A Harmon DC Kobayashi W Chen YL Yock TI Ebb DH Choy E Raskin KA Liebsch N Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma Cancer 2011 117 19 4522 4530 10.1002/cncr.26037 21448934 PMC3716000 · DOI · Paper page
  66. [81]Imai R Kamada T Sugahara S Tsuji H Tsujii H Br J Radiol. 2011 84 1 48 54 10.1259/bjr/13783281 PMC3473887 21427182 · DOI
  67. [82]Staab Al Rutz HP Ares C Timmermann B Schneider R Bolsi A Albertini F Lomax A Goitein G Hug E Spot-scanning-based proton therapy for extracranial chordoma Int J Radiat Oncol Biol Phys. 2011 81 4 489 496 10.1016/j.ijrobp.2011.02.018 21497457 · DOI
  68. [84]Salunke AA Chen Y Tan JH Chen X Khin LW Puhaindran ME Does pathological fracture affect the prognosis in patients with osteosarcoma of the extremities? a systematic review and meta-analysis Bone Joint J. 2014 96 1396 1403 10.1302/0301-620X.96B10.34370 25274928 · DOI
  69. [85]Xie C Guo W Li Y Sun X Pathological fracture does not influence local recurrence and survival in high-grade extremity osteosarcoma with adequate surgical margins J Surg Oncol 2012 106 7 820 825 10.1002/jso.23150 22740310 · DOI
  70. [86]Reddy KI Wafa H Gaston CL Grimer RJ Abudu AT Jeys LM Carter SR Tillman RM Does amputation offer any survival benefit over limb salvage in osteosarcoma patients with poor chemonecrosis and close margins? Bone Joint J. 2015 97 1 115 120 10.1302/0301-620X.97B1.33924 25568424 · DOI
  71. [87]Bramer JA Abudu AA Grimer RJ Carter SR Tillman RM Do pathological fractures influence survival and local recurrence rate in bony sarcomas? Eur J Cancer 2007 43 13 1944 1951 10.1016/j.ejca.2007.07.004 17698347 · DOI
  72. [88]Carrle D, Bielack S. Osteosarcoma lung metastases detection and principles of multimodal therapy. In: Jaffe et al, editor. Pediatric and Adolescent Osteosarcoma: Cancer Treatment and Research, 152. DOI 10.1007/978-1-4419-0284-9_8. Springer Science+Business Media, LLC 2009. 20213390 · DOI
  73. [89]Bacci G Ferrari S Bertoni F Rimondini S Longhi A Bacchini P Forni C Manfrini M Donati D Picci P Prognostic factors in nonmetastatic Ewing’s sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli J Clin Oncol 2000 18 4 11 10623687
  74. [90]Altaf S Enders F Jeavons E Krailo M Barkauskas DA Meyers P Arndt C High BMI at diagnosis is associated with inferior survival in patients with osteosarcoma: a report from the Children’s Oncology Group Pediatr Blood Cancer 2013 60 12 2042 2046 23955975
  75. [91]Collins M Wilhelm M Conyers R Herschtal A Whelan J Bielack S Kager L Kühne T Sydes M Gelderblom H Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis J Clin Oncol 2013 31 2310 2312 23669227
  76. [92]Janeway KA Barkauskas DA Krailo MD Meyers PA Schwartz CL Ebb DH Seibel NL Grier HE Gorlick R Marina N Outcome for adolescent and young adult patients with osteosarcoma Cancer 2012 118 18 4579 4605 10.1002/cncr.27414 22252521 PMC4008337 · DOI
  77. [93]Bielack S Carrle D Casali PG ESMO Guidelines Working Group. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol. 2009 20 4 137 139 19454435
  78. [94]Grimer RJ Surgical options for children with osteosarcoma Lancet Oncol. 2005 6 2 85 92 10.1016/S1470-2045(05)01734-1 15683817 · DOI
  79. [95]Lewis IJ Nooij MA Whelan J Sydes MR Grimer R Hogendoorn PC Memon MA Weeden S Uscinska BM van Glabbeke M The MRC BO06 and EORTC 80931 collaborators and European osteosarcoma intergroup: improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European osteosarcoma intergroup J Natl Cancer Inst. 2007 99 112 128 10.1093/jnci/djk015 17227995 · DOI
  80. [97]Goorin AM Schwartzentruber DJ Devidas M Gebhardt MC Ayala AG Harris MB Helman LJ Grier HE Link MP Pediatric Oncology Group Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651 J Clin Oncol 2003 21 1574 1580 10.1200/JCO.2003.08.165 12697883 · DOI
  81. [99]Daw NC Neel MD Rao BN Billups CA Wu J Jenkins JJ Quintana J Luchtman-Jones L Villarroel M Santana VM Frontline treatment of localized osteosarcoma without methotrexate: results of the St Jude Children’s Research Hospital OS99 trail Cancer 2011 117 12 2770 2778 10.1002/cncr.25715 21656756 PMC3535449 · DOI
  82. [100]Picci P Sangiorgi L Rougraff BT Neff JR Casadei R Campanacci M Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma J Clin Oncol 1994 12 2699 2705 7989947
  83. [102]Goorin AM Harris MB Bernstein M Ferguson W Devidas M Siegal GP Gebhardt MC Schwartz CL Link M Grier HE Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a Pediatric Oncology Group trial J Clin Oncol 2002 20 2 426 433 10.1200/JCO.20.2.426 11786570 · DOI
  84. [103]Navid F Willert JR McCarville MB Furman W Watkins A Roberts W Daw NC Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma Cancer 2008 113 2 419 425 10.1002/cncr.23586 18484657 · DOI
  85. [104]Eiber F Guiliano A Eckhardt J Patterson K Moseley S Goodnight J Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial J Clin Oncol 1987 5 21 26 3543236
  86. [105]Bernthal NM Federman N Eilber FR Nelson SD Eckardt JJ Eilber FC Tap WD Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy ion patients with high-grade, operable osteosarcoma Cancer 2012 118 5888 5893 10.1002/cncr.27651 22648705 · DOI
  87. [106]van Dalen EC, van As JW, de Camargo B. Methotrexate for high-grade osteosarcoma in children and young adults Review. London: Wiley; 2009. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006325.pub3/full. Accessed 20 Jan 2016. 19160278 · DOI
  88. [107]Whelan J Patterson D Perisoglou M Bielack S Marina N Smeland S Bernstein M The role of interferons in the treatment of osteosarcoma Pediatr Blood Cancer 2010 54 3 350 354 10.1002/pbc.22136 19902521 · DOI
  89. [108]Whelan J Bielack SS Marina N Smeland S Jovic G Hook JM Krailo M Anninga J Butterfass-Bahloul T Böhling T EURAMOS collaborators. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment Ann Oncol 2015 26 407 414 10.1093/annonc/mdu526 25421877 PMC4304379 · DOI
  90. [109]Bielack SS Smeland S Whelan JS Marina N Jovic G Hook JM Krailo MD Gebhardt M Pápai Z Meyer J EURAMOS-1 investigators. Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 Good Response Randomized Controlled Trial J Clin Oncol 2015 33 20 2279 2287 10.1200/JCO.2014.60.0734 26033801 PMC4486345 · DOI · Paper page
  91. [111]Byun BH Kong CB Lim I Kim BI Choi CW Song WS Cho WH Jeon DG Koh JS Lee SY Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential 18 F-FDG PET/CT and MRI Eur J Nucl Med Mol Imag. 2013 41 1553 1562 10.1007/s00259-014-2746-2 24652233 · DOI
  92. [112]Wang CS Du LJ Si MJ Yin QH Chen L Shu M Yuan F Fei XC Ding XY Noninvasive assessment of response to neoaduvant chemotherapy in osteosarcoma of long bones with diffusion-weighted imaging: an initial in vivo study PLoS One 2013 8 8 e72679 10.1371/journal.pone.0072679 23991141 PMC3753340 · DOI
  93. [113]National Institute for Health and Care Excellence (NICE) Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients. NICE Guidelines [CG151]; 2012. http://www.nice.org.uk/guidance/cg151. Accessed 02 Feb 2015. 26065059
  94. [114]Frezza AM Beale T Bomanji J Jay A Kalavrezos N Dileo P Whelan J Strauss SJ Is [F-18]-fluorodeoxy-d-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment? BMC Cancer 2014 14 23 29 10.1186/1471-2407-14-23 24422949 PMC3904418 · DOI
  95. [115]Kager L Zoubek A Potschger U Kastner U Flege S Kempf-Bielack B Branscheid D Kotz R Salzer-Kuntschik M Winkelmann W Cooperative German-Austrian-Swiss Osteosarcoma Study Group. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols J Clin Oncol 2003 21 2011 2018 10.1200/JCO.2003.08.132 12743156 · DOI · Paper page
  96. [116]Gelderblom H Jinks RC Sydes M Bramwell VH van Glabbeke M Grimer RJ Hogendoorn PC McTiernan A Lewis IJ Nooij MA European Osteosarcoma Intergroup. Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials Eur J Cancer 2011 47 6 895 902 10.1016/j.ejca.2010.11.036 21216138 · DOI
  97. [117]Garcia Franco CE Torre W, Tamura A, Guillén-Grima F, San-Julian M, Martin-Algarra S, Pardo FJ. Long-term results after resection for bone sarcoma pulmonary metastases Eur J Cardiothorac Surg 2010 37 1205 1208 10.1016/j.ejcts.2009.11.026 20022760 · DOI
  98. [118]Ferrari S Briccoli A Mercuri M Bertoni F Picci P Tienghi A Del Prever AB Fagioli F Comandone A Bacci G Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival J Clin Oncol 2003 21 710 715 10.1200/JCO.2003.03.141 12586810 · DOI · Paper page
  99. [119]Kempf-Bielack B Bielack SS Juergens H Branscheid D Berdel WE Exner GU Göbel U Helmke K Jundt G Kabisch H Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the cooperative osteosarcoma study group (COSS) J Clin Oncol 2005 23 3 559 568 10.1200/JCO.2005.04.063 15659502 · DOI · Paper page
  100. [120]Berger M Grignani G Ferrari S Biasin E Brach del Prever A, Aliberti S, Saglio F, Aglietta M, Fagioli F. Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high risk osteosarcoma patients Cancer 2009 115 2980 2987 10.1002/cncr.24368 19452540 · DOI
  101. [121]Munoz A Alfaro J Pardo N García-Miguel P Quintero V Gros L Melero C Antuña MJ Ocete G de Las Heras J Long-term results of the Spanish protocol SO-95 for the treatment of non-metastatic high-grade osteosarcoma of the extremeties in children Clin Translat Oncol. 2009 11 387 392 10.1007/s12094-009-0373-3 19531454 · DOI
  102. [122]Anderson PM Subbiah V Rohren E Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223 Adv Exp Med Biol 2014 804 291 304 10.1007/978-3-319-04843-7_16 24924181 · DOI
  103. [123]Grignani G Palmerini E Ferraresi V D’Ambrosio L Bertulli R Asaftei SD Tamburini A Pignochino Y Sangiolo D Marchesi E Italian Sarcoma Group. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial Lancet Oncol 2015 16 1 98 107 10.1016/S1470-2045(14)71136-2 25498219 · DOI
  104. [124]Buddingh EP Anninga JK Versteegh MI Taminiau AH Egeler RM van Rijswijk CS Hogendoorn PC Lankester AC Gelderblom H Prognostic factors in pulmonary metastasized high grade osteosarcoma Paediat Blood Cancer. 2010 54 216 221 19890902
  105. [125]He JP Hao Y Li M Wang J Guo FJ Tumor-to-background ratio to predict response to chemotherapy of osteosarcoma better than standard uptake values Orthop Surg. 2014 6 2 145 153 10.1111/os.12102 24890297 PMC6583510 · DOI
  106. [126]Leavey PJ Mascarenhas L Marina N Chen Z Krailo M Miser J Brown K Tarbell N Bernstein ML Granowetter L Children’s Oncology Group. Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: a report from the Children’s Oncology Group Pediatr Blood Cancer 2008 51 334 338 10.1002/pbc.21618 18506764 PMC2728357 · DOI
  107. [127]Bacci G Forni C Longhi A Ferrari S Donati D De Paolis M Barbieri E Pignotti E Rosito P Versari M Long-term outcome for patients with non-metastatic Ewing’s sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992 Eur J Cancer 2004 40 73 83 10.1016/j.ejca.2003.08.022 14687792 · DOI
  108. [128]Paulussen M Ahrens S Craft AW Dunst J Fröhlich B Jabar S Rübe C Winkelmann W Wissing S Zoubek A Jürgens H Ewing’s tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing’s Sarcoma Studies patients J Clin Oncol 1998 16 3044 3052 9738574
  109. [129]Bacci G Palmerini E Staals EL Longhi A Barbieri E Alberghini M Ferrari S Ewing’s sarcoma family tumours of the humerus: outcome of patients treated with radiotherapy, surgery or surgery and adjuvant radiotherapy Radiother Oncol 2009 93 383 387 10.1016/j.radonc.2009.06.009 19576648 · DOI
  110. [130]Schuck A Ahrens S Paulussen M Kuhlen M Könemann S Rübe C Winkelmann W Kotz R Dunst J Willich N Jürgens H Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials Int J Radiat Oncol Biol Phys 2003 55 168 177 10.1016/S0360-3016(02)03797-5 12504050 · DOI
  111. [132]Nesbit ME Gehan EA Burgert EO Jr Vietti TJ Cangir A Tefft M Evans R Thomas P Askin FB Kissane JM Multimodal therapy for the management of primary, nonmetastatic Ewing’s sarcoma of bone: a long-term follow-up of the first intergroup study J Clin Oncol 1990 8 1664 1674 2213103
  112. [133]Grier HE Krailo MD Tarbell NJ Link MP Fryer CJ Pritchard DJ Gebhardt MC Dickman PS Perlman EJ Meyers PA Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone New Eng J Med. 2003 348 694 701 10.1056/NEJMoa020890 12594313 · DOI
  113. [134]Jürgens H Exner U Gadner H Harms D Michaelis J Sauer R Treuner J Voûte T Winkelmann W Winkler K Multidisciplinary treatment of primary Ewing’s sarcoma of bone: a 6-year experience of a European cooperative trial Cancer 1988 61 23 32 10.1002/1097-0142(19880101)61:1<23::AID-CNCR2820610106>3.0.CO;2-M 3334950 · DOI
  114. [135]Paulussen M Craft AW Lewis I Hackshaw A Douglas C Dunst J Schuck A Winkelmann W Köhler G Poremba C European Intergroup Cooperative Ewing’s Sarcoma Study-92. Results of the EICESS-92 study: two randomized trials of Ewing’s sarcoma treatment—cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients J Clin Oncol 2008 26 27 4385 4393 10.1200/JCO.2008.16.5720 18802150 · DOI
  115. [136]Pinkerton CR Bataillard A Guillo S Oberlin O Fervers B Philip T Treatment strategies for metastatic Ewing’s sarcoma Eur J Cancer 2001 37 1338 1344 10.1016/S0959-8049(01)00131-9 11435062 · DOI
  116. [137]Wagner LM McAllister N Goldsby RE Rausen AR McNall-Knapp RY McCarville MB Albritton K Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma Pediat Blood Cancer. 2007 48 132 139 10.1002/pbc.20697 16317751 · DOI
  117. [138]Burdach S Meyer-Bahlburg A Laws HJ Haase R van Kaik B Metzner B Wawer A Finke R Göbel U Haerting J High-dose therapy for patients with primary multifocal and early relapsed Ewing’s tumors: results of two consecutive regimens assessing the role of total-body irradiation J Clin Oncol 2003 21 3072 3078 10.1200/JCO.2003.12.039 12915596 · DOI
  118. [139]Le Deley M-C Paulussen M Lewis I Brennan B Ranft A Whelan J Le Teuff G Michon J Ladenstein R Marec-Brard P Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the Randomized Noninferiority Euro-EWING99-R1 Trial J Clin Oncol 2014 32 23 2440 2448 10.1200/JCO.2013.54.4833 24982464 · DOI
  119. [140]Womer RB West DC Krailo MD Dickman PS Pawel BR Grier HE Marcus K Sailer S Healey JH Dormans JP Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s Oncology Group J Clin Oncol 2012 30 4148 4154 10.1200/JCO.2011.41.5703 23091096 PMC3494838 · DOI
  120. [141]Ferrari S Sundby Hall K Lutsch R Tienghi A Wiebe T Fagioli F Alvegard TA Brach Del Prever A Tamburini A Alberghini M Nonmetastatic Ewing family tumours: high-dose chemotherapy with stem cell rescue on poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol Ann Oncol 2011 22 5 1221 1227 10.1093/annonc/mdq573 21059639 · DOI
  121. [142]Juergens C Weston C Lewis I Whelan J Paulussen M Oberlin O Michon J Zoubek A Jürgens H Craft A Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial Pediat Blood Cancer 2006 47 1 22 29 10.1002/pbc.20820 16572419 · DOI
  122. [143]Ladenstein R Potschger U Le Deley MC Whelan J Paulussen M Oberlin O van den Berg H Dirksen U Hjorth L Michon J Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial J Clin Oncol 2010 28 3284 3291 10.1200/JCO.2009.22.9864 20547982 · DOI
  123. [144]Ferrari S del Prever AB Palmerini E Staals E Berta M Balladelli A Picci P Fagioli F Bacci G Vanel D Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma Pediatr Blood Cancer 2009 52 5 581 584 10.1002/pbc.21917 19142994 · DOI
  124. [145]Saylors RL 3rd Stine KC Sullivan J Kepner JL Wall DA Bernstein ML Harris MB Hayashi R Vietti TJ; Pediatric Oncology Group. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study J Clin Oncol 2001 19 15 3463 3469 11481351
  125. [146]Casey DA Wexler LH Merchant MS Chou AJ Merola PR Price AP Meyers PA Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience Pediatr Blood Cancer 2009 53 6 1029 1034 10.1002/pbc.22206 19637327 · DOI
  126. [147]McTiernan A Driver D Michelagnoli MP Kilby AM Whelan JS High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing’s sarcoma family of tumours Ann Oncol 2006 17 1301 1305 10.1093/annonc/mdl108 16782749 · DOI
  127. [148]Fox E Patel S Wathen JK Schuetze S Chawla S Harmon D Reinke D Chugh R Benjamin RS Helman LJ Phase II Study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of sarcoma alliance for research through collaboration study 003 Oncol. 2012 17 3 321 10.1634/theoncologist.2010-0265 PMC3316916 22363068 · DOI
  128. [149]Mora J Cruz CO Parareda A de Torres C Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel J Pediatr Hematol Oncol 2009 31 10 723 729 10.1097/MPH.0b013e3181b2598c 19727011 · DOI
  129. [150]Kebudi R Gorgun O Ayan I Oral etoposide for recurrent/progressive sarcomas of childhood Pediatr Blood Cancer 2004 42 4 320 324 10.1002/pbc.10393 14966827 · DOI
  130. [152]Indelicato DJ Keole SR Shahlaee AH Shi W Morris CG Marcus RB Jr Definitive radiotherapy for Ewing tumors of extremities and pelvis: long-term disease control, limb function, and treatment toxicity Int J Radiat Oncol Biol Phys 2008 72 3 871 877 10.1016/j.ijrobp.2008.02.023 18455323 · DOI
  131. [153]DuBois SG Krailo MD Gebhardt MC Donaldson SS Marcus KJ Dormans J Shamberger RC Sailer S Nicholas RW Healey JH Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children’s Oncology Group Cancer 2015 121 3 467 475 10.1002/cncr.29065 25251206 PMC4305012 · DOI
  132. [154]Patel S Delaney T Advanced-technology radiation therapy for bone sarcomas Cancer Control. 2008 15 1 21 37 18094658
  133. [155]Sterzing F Stoiber EM Nill S Bauer H Huber P Debus J Münter MW Intensity modulated radiotherapy (IMRT) in the treatment of children and adolescents–a single institution’s experience and a review of the literature Radiat Oncol 2009 4 37 10.1186/1748-717X-4-37 19775449 PMC2760561 · DOI
  134. [156]Mounessi FS Lehrich P Haverkamp U Willich N Bolling T Eich HT Pelvic Ewing sarcomas. Three-dimensional conformal vs. intensity-modulated radiotherapy Strahlenther Onkol 2013 189 4 308 314 10.1007/s00066-012-0304-z 23443613 · DOI
  135. [157]Pérez-Muñoz I Grimer RJ Spooner D Carter S Tillman RRR Abudu A Jeys L Use of tissue expander in pelvic Ewing’s sarcoma treated with radiotherapy Eur J Surg Oncol 2014 40 2 197 201 10.1016/j.ejso.2013.09.001 24084085 · DOI
  136. [158]Euro-Ewing Radiotherapy Guidelines, Chapter XVII. In: EUROpean Ewing tumour Working Initiative of National Groups Ewing Tumour Studies 1999. EE 99 Amended Version 14th February 2006. https://www.skion.nl/workspace/uploads/ee99_amended_treo__2006_02_14.pdf. Accessed 20 Jan 2016.
  137. [159]Bernstein ML Devidas M Lafreniere D Souid AK Meyers PA Gebhardt M Stine K Nicholas R Perlman EJ Dubowy R Pediatric Oncology Group Children’s Cancer Group Phase II Study 9457 Children’s Oncology Group Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children’s Cancer Group Phase II Study 9457—a report from the Children’s Oncology Group J Clin Oncol 2006 24 152 159 10.1200/JCO.2005.02.1717 16382125 · DOI
  138. [160]Whelan JS Burcombe RJ Janinis J Baldelli AM Cassoni AM A systematic review of the role of pulmonary irradiation in the management of primary bone tumours Ann Oncol 2002 13 23 30 10.1093/annonc/mdf047 11863105 · DOI
  139. [161]Brown LC Lester RA Grams MP Haddock MG Olivier KR Arndt CA Rose PS Laack NN Stereotactic radiotherapy for metastatic and recurrent Ewing sarcoma and osteosarcoma Sarcoma. 2014 418270 9 PMC4274855 25548538
  140. [162]Cotterill SJ Ahrens S Paulussen M Jürgens HF Voûte PA Gadner H Craft AW Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group J Clin Oncol 2000 18 3108 3114 10963639
  141. [163]Cangir A Vietti TJ Gehan EA Burgert EO Jr Thomas P Tefft M Nesbit ME Kissane J Pritchard D Ewing’s sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing’s sarcoma studies Cancer 1990 66 887 893 10.1002/1097-0142(19900901)66:5<887::AID-CNCR2820660513>3.0.CO;2-R 2201433 · DOI
  142. [164]McTiernan AM Cassoni AM Driver D Michelagnoli MP Kilby AM Whelan JS Improving outcomes after relapse in Ewing’s Sarcoma: analysis of 114 patients from a single institution Sarcoma. 2006 2006 1 8 PMC1698143 17496997
  143. [165]Stahl M Ranft A Paulussen M Bölling T Vieth V Bielack S Görtitz I Braun-Munzinger G Hardes J Jürgens H Risk of recurrence and survival after relapse in patients with Ewing sarcoma Pediatr Blood Cancer 2011 57 4 549 553 10.1002/pbc.23040 21442722 · DOI
  144. [166]Abudu A Davies AM Pynsent PB Mangham DC Tillman RM Carter SR Grimer RJ Tumour volume as a predictor of necrosis after chemotherapy in Ewing’s sarcoma J Bone Joint Surg Br 1999 81 2 317 322 10.1302/0301-620X.81B2.8979 10204943 · DOI
  145. [167]Boriani S Bandiera S Biagini R Bacchini P Boriani L Cappuccio M Chevalley F Gasbarrini A Picci P Weinstein JN Chordoma of the mobile spine: 50 years of experience Spine. 2006 31 493 503 10.1097/01.brs.0000200038.30869.27 16481964 · DOI
  146. [168]Xie L Whalley N Adasonia K Grimer R Jeys L Can local recurrence of a sacral chordoma be treated by further surgery? Bone Joint J. 2015 97 5 711 715 10.1302/0301-620X.97B5.35131 25922468 · DOI
  147. [169]Stacchiotti S Marrari A Tamborini E Palassini E Virdis E Messina A Crippa F Morosi C Gronchi A Pilotti S Response to imatinib plus sirolimus in advanced chordoma Ann Oncol 2009 20 1886 1894 10.1093/annonc/mdp210 19570961 · DOI
  148. [170]Stacchiotti S Longhi A Ferraresi V Grignani G Comandone A Stupp R Bertuzzi A Tamborini E Pilotti S Messina A Phase II study of imatinib in advanced chordoma J Clin Oncol 2012 30 9 914 920 10.1200/JCO.2011.35.3656 22331945 · DOI
  149. [171]Brewer P Sumathi V Grimer RJ Carter SR Tillman RM Abudu A Jeys L Primary leiomyosarcoma of bone: analysis of prognosis Sarcoma. 2012 636849 4 PMC3329678 22550421
  150. [173]Chawla S Henshaw R Seeger L Choy E Blay JY Ferrari S Kroep J Grimer R Reichardt P Rutkowski P Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study Lancet Oncol. 2013 14 9 901 908 10.1016/S1470-2045(13)70277-8 23867211 · DOI
  151. [174]Rutkowski P Ferrari S Grimer RJ Stalley PD Dijkstra SP Pienkowski A Vaz G Wunder JS Seeger LL Feng A Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone Ann Surg Oncol 2015 22 9 2860 2868 10.1245/s10434-015-4634-9 26033180 PMC4531146 · DOI
  152. [175]Thomas D Henshaw R Skubitz K Chawla S Staddon A Blay JY Roudier M Smith J Ye Z Sohn W Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study Lancet Oncology. 2010 11 3 275 280 10.1016/S1470-2045(10)70010-3 20149736 · DOI
  153. [176]Fleming GF Heimann PS Stephens JK Simon MA Ferguson MK Benjamin RS Samuels BL Dedifferentiated chordoma. Response to aggressive chemotherapy in two cases Cancer 1993 72 3 714 718 10.1002/1097-0142(19930801)72:3<714::AID-CNCR2820720314>3.0.CO;2-1 8334623 · DOI
  154. [177]George S Merriam P Maki RG Van den Abbeele AD Yap JT Akhurst T Harmon DC Bhuchar G O’Mara MM D’Adamo DR Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas J Clin Oncol 2009 27 19 3154 3160 10.1200/JCO.2008.20.9890 19451429 PMC2716937 · DOI
  155. [178]Puri A Gulia A Hawaldar R Ranganathan P Badwe RA Does intensity of surveillance affect survival after surgery for sarcomas? results of a randomized noninferiority trial Clin Orthop Rel Res. 2014 472 5 1568 1575 10.1007/s11999-013-3385-9 PMC3971232 24249538 · DOI
  156. [179]Aksnes LH Bauer HC Dahl AA Fosså SD Hjorth L Jebsen N Lernedal H Hall KS Health status at long-term follow up in patients treated for extremity localized Ewing sarcoma or osteosarcoma: a Scandinavian sarcoma group study Pediatr Blood Cancer 2009 53 84 89 10.1002/pbc.22027 19343771 · DOI
  157. [180]Langer T Stöhr W Paulides M Kremers A Dörr HG Göbel U Beck JD Prospective multicenter registration of major late sequelae in sarcoma patients using the late effects surveillance system (LESS) Klinische Pädiatrie 2005 217 176 181 10.1055/s-2005-836503 15858710 · DOI
  158. [181]Bassal M Mertens AC Taylor L Neglia JP Greffe BS Hammond S Ronckers CM Friedman DL Stovall M Yasui YY Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the childhood cancer survivor study Clin Oncol 2006 24 3 476 483 10.1200/JCO.2005.02.7235 16421424 · DOI
  159. [182]Rodriguez-Galindo C Poquette C Marina NM Head DR Cain A Meyer WH Santana VM Pappo AS Hematologic abnormalities and acute myeloid leukemia in children and adolescents administered intensified chemotherapy for the Ewing sarcoma family of tumours J Pediat Oncol 2000 22 4 321 329 10.1097/00043426-200007000-00008 10959902 · DOI

Cited by

Sorted by citations

Authors
On behalf of the British Sarcoma Group, Gerrand, C., Athanasou, N., Brennan, B., Grimer, R., Judson, I., Morland, B., Peake, D., Seddon, B., & Whelan, J.
Affiliations
  • Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
  • Nuffield Orthopaedic Centre (GB)
  • Royal Orthopaedic Hospital (GB)
  • Birmingham Children's Hospital (GB)
  • Queen Elizabeth Hospital Birmingham (GB)
  • University College Hospital (GB)
Corresponding author
Gerrand, Craig
ORCID
Venue
Clinical Sarcoma Research
Publisher
Springer Science and Business Media LLC
Published
2016-05-04
Volume
6
Issue
1
Pages
7-7
ISSN
2045-3329 (ISSN-L)
DOI
10.1186/s13569-016-0047-1
PMC
PMC4855334
OpenAlex
W2346235649
Cited by
258
References
4
Citations by year
2026: 17 · 2025: 29 · 2024: 27 · 2023: 19 · 2022: 30 · 2021: 42 · 2020: 40 · 2019: 20 · 2018: 18 · 2017: 8 · 2016: 3 · 2015: 2 · 2014: 2 · 2013: 1
FWCI
2.83
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Clinical Sarcoma Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Sarcoma UK (Funding for editorial work only)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
  • Health Sciences › Medicine › Rheumatology › Bone Tumor Diagnosis and Treatments
  • Health Sciences › Medicine › Surgery › Management of metastatic bone disease
Keywords
bone sarcoma, primary bone tumors, clinical management guidelines, multidisciplinary care, specialist referral, follow-up schedule, cancer types

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review